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Summary
Barth syndrome is an X-linked cardiomyopathy with
neutropenia and 3-methylglutaconic aciduria. Recently,
mutations in the G4.5 gene, located in Xq28, have been
described in four probands with Barth syndrome. We
have now evaluated 14 Barth syndrome pedigrees for
mutations in G4.5 and have identified unique mutations
in all, including four splice-site mutations, three
deletions, one insertion, five missense mutations, and
one nonsense mutation. Nine of the 14 mutations are
predicted to significantly disrupt the protein products of
G4.5. The occurrence of missense mutations in exons 3
and 8 suggests that these exons encode essential portions
of the G4.5 proteins, whose functions remain unknown.
We found no correlation between the location or type
of mutation and any of the clinical or laboratory
abnormalities of Barth syndrome, which suggests that
additional factors modify the expression of the Barth
phenotype. The characterization of mutations of the
G4.5 gene will be useful for carrier detection, genetic
counseling, and the identification of patients with Barth
syndrome who do not manifest all of the cardinal
features of this disorder.
Introduction
X-linked cardiomyopathy with neutropenia, growth re-
tardation, and increased 3-methylglutaconic aciduria is
a rare but well-known metabolic disorder of childhood,
commonly known as “Barth syndrome” (Barth et al.
1983; Kelley et al. 1991; Christodoulou et al. 1994).
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Despite extensive studies during the past 20 years, the
primary genetic defect causing Barth syndrome was un-
known until recently. After the mapping of Barth syn-
drome to Xq28.12 (Bolhuis et al. 1991), Bione et al.
(1996) identified, in patients with Barth syndrome, ap-
parently disabling mutations of G4.5, one of several ex-
pressed sequences from this small region of the X chro-
mosome. G4.5 is a relatively small but complex gene
incorporating 11 exons, two ATG initiation sites, and
multiple alternative splicings of exons 5–7 that generate
a family of mRNAs with tissue-specific distributions.
The predicted protein sequences encoded by the G4.5
gene have no identifiable homology with other known
proteins, thus making their function unknown at this
time.
In the initial description of Barth syndrome and in
many subsequent case reports, a number of mitochon-
drial abnormalities, both metabolic and histologic, have
been described (Neustein et al. 1979; Barth et al. 1983,
1996). The presence of increased 3-methylglutaconic ac-
iduria and low blood cholesterol levels have also been
observed in the majority of Barth syndrome patients
(Kelley et al. 1991). However, despite the well-known
link between 3-methylglutaconic aciduria and choles-
terol metabolism, no abnormality of cholesterol or poly-
isoprenoid biosynthesis has been found in Barth syn-
drome (Gibson et al. 1991). Although there have been
reports of clinical improvement of Barth syndrome pa-
tients treated with carnitine or pantothenic acid, no ther-
apy has been universally beneficial, and none has sig-
nificantly altered the 3-methylglutaconic aciduria (Ino et
al. 1988; Kelley et al. 1991; Ostman-Smith et al. 1994).
During the past 15 years, we have identified and
treated Barth syndrome patients from 14 different fam-
ilies manifesting a wide range of phenotypes. This large
number of families provides an unusual opportunity to
examine the correlation between phenotype and specific
mutations of the G4.5 gene. We describe here our results
of mutational analysis of patients and heterozygotes
from these 14 pedigrees and discuss the relationship be-
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Table 1
Oligonucleotide Primers Used in Sequencing and PCR Reactions
Primer Primer Sequence Location
Forward:
F1 5′-GGAGAAGGGCCTGTTTCATTGAG-3′ Intron 5
F2 5′-CCTGGACCCTGGCCAGCAGCGTCG-3′ Exon 1
F3 5′-GCTGGCACAGAAGCTTGG-3′ Intron 7
F4 5′-GAAGTCAGGCTGGGGCAG-3′ Intron 9
F5 5′-TTTGGGCTGTAGGGAAATGG-3′ Intron 2
F6 5′-AAGGGGACAGGTGCTGAGAC -3′ Intron 7
F7 5′-CTTCCCGTTTCCTCCCGTTC-3′ Exon 1
F8 5′-GCCTGATTGCTGAGTGTCATCTC-3′ Exon 8
F9 5′-ACAGAGATTAAGCTGCTGGC-3′ Intron 4
F12 5′-CCTCCCTTCTGCATGCTGATGC-3′ Intron 3
Reverse:
R1 5′-GCTTGAGTGATCCTCTCACCTC-3′ Intron 5
R2 5′-CGACATGCCACAGGGGCAGGA-3′ Exon 8
R3 5′-CCTCCCCCTGCCCAGCAC-3′ Intron 2
R4 5′-GCCCCAGAAGTGCCTCCC-3′ Intron 4
R5 5′-CCAGGGCTCCATGAAAAGGC-3′ Intron 2
R6 5′-CCTGCAGCTGGCCTCCATAG-3′ Intron 9
R7 5′-TGACGGGATGGAGAGGGTGGAG-3′ Intron 10
R8 5′-CTACAAACACGCCCATCTACCC-3′ Intron 7
R9 5′-AGATGTGGCGGAGTTTCAGG-3′ Exon 3
R10 5′-AGCTCGGAGAGGGCACTTGAG-3′ Exon 11




The diagnosis of Barth syndrome was based on the
triad of dilated cardiomyopathy, neutropenia, and in-
creased 3-methylglutaconic aciduria in males. The clin-
ical histories of most of these subjects have been reported
elsewhere (Kelley et al. 1991; Christodoulou et al. 1994).
Lymphocytes from each proband were immortalized by
Epstein-Barr virus transformation, and the derived cell
lines were used as the source of DNA and RNA for all
sequencing. DNA from other members of individual
pedigrees was extracted from whole blood or from sim-
ilarly prepared lymphoblast lines, by use of a kit from
Gentra Systems. The collection and use of archived pa-
tient samples was approved by the institutional review
board of one of the investigators (R.I.K.).
PCR Amplification
The exon regions of G4.5 were amplified in three frag-
ments from primer pairs F7/R5, F5/R1, and F1/R10 (ta-
ble 1). Genomic DNA (500 ng) was PCR amplified with
25 pmol of each primer in 1# Taq buffer consisting of
16.6 mM (NH4)2SO4, 16.6 mM Tris-HCl (pH 8.8), 6.7
mM EDTA, 6.7 mM MgCl2, 10 mM b-mercaptoethanol
with the addition of 5% dimethyl sulfoxide, 1 mM
dNTP, and 1.5 units of AmpliTaq DNA polymerase (Per-
kin Elmer). After denaturation at 94C for 3 min, PCR
was performed by 30 cycles of denaturation at 94C for
1 min, annealing at 60C for 1 min, and extension at
72C for 2 min, followed by extension at 72C for 7
min, in a Perkin Elmer 9600 thermal cycler. PCR prod-
ucts were separated on a 1% agarose gel and were pu-
rified by use of QIAquick gel extraction kits (Qiagen).
PCR fragments were cloned by use of the Original TA
Cloning kit (Invitrogen).
Reverse Transcriptase–PCR (RT-PCR)
Total RNA was isolated from lymphoblasts by use of
Trizol (Promega), according to manufacturer’s direc-
tions. RNA (1 mg) was reverse transcribed in 1 # Taq
buffer (Perkin Elmer) with 2.5 mM dNTP, 20 units of
RNasin, 50 units of avaian myeloblastosis virus RT, and
250 ng of Oligo dT (Promega). A 5-ml aliquot of the
cDNA was PCR amplified with 25 pmol each of primers
F2 and R9 (table 1) in 1 # Taq buffer (Perkin Elmer)
with the addition of 0.5 mM dNTP, 1.5 units of
AmpliTaq DNA polymerase (Perkin Elmer), and 3.5 mM
MgCl2. After denaturation at 94C for 3 min, PCR was
performed by 30 cycles of denaturation at 94C for 1
min, annealing at 58C for 1 min, and extension at 72C
for 1 min, followed by extension at 72C for 7 min, in
a Perkin Elmer 9600 thermal cycler. Products were an-
alyzed on a 4% NuSieve (FMC) agarose gel and were
isolated by use of QIAquick gel extraction kits (Qiagen)
for direct DNA sequencing.
DNA Sequencing
Sequencing of cloned fragments was performed by use
of the Cy5 Autoread DNA sequencing kit (Pharmacia
Biotech), according to the manufacturer’s instructions.
Reaction products were loaded onto a 6% Long Ranger
gel (FMC) and were analyzed by use of an ALFexpress
DNA sequencer. Direct DNA sequencing was performed
by use of the Perkin Elmer ABI prism dye terminator
cycle sequencing kit with AmpliTaq DNA polymerase.
The reactions were spun through Centriflex columns
(AGCT) according to the manufacturer’s instructions,
and the eluates were spun to dryness. Samples were re-
suspended in 6 ml of 5:1 formamide:25 mM EDTA (pH
8.0) containing 50 mg blue dextran/ml, and 3 ml was
then heated at 90C for 2 min, loaded onto a 5% Long
Ranger gel (FMC), and analyzed by use of a Perkin El-
mer ABD 377 DNA sequencer at the Molecular Biology
Core Facility of The duPont Hospital for Children. All
sequences were analyzed by use of Macvector software
(IBI). Primers used in sequencing are listed in table 1.
Restriction Digest
The detection of mutations in carrier females or in
other affected males in each pedigree, as well as analysis
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of control chromosomes, was accomplished by either
direct sequencing or restriction-enzyme digestion of a
site created by the mutation (table 2). Enzymes included
KpnI, AvaII, and ApaI (Promega) and AlwNI and SfaNI
(NEB). Digestions were performed in 1# reaction buf-
fer, according to the manufacturer’s specifications, at
37C for 1 h and were analyzed on a 4% NuSieve (FMC)
agarose gel.
Results
Identification of G4.5 Mutations
All 14 probands with a clinical diagnosis of Barth
syndrome were found to have mutations present in G4.5,
as listed in table 2; 4 probands had splice-site mutations,
4 had deletions or insertions that would lead to frame-
shift mutations, 5 had missense mutations, and 1 had a
nonsense mutation. Each of the mutations detected in
the 14 pedigrees was unique, and all were different from
those previously reported by Bione et al. (1996).
All four splice-site mutations were located in the first
two introns (fig. 1). Three of the four splice-site muta-
tions affected splice-donor sites, two having different
nucleotide changes at the 5 position in intron 1 and
the other having a change at the 2 position in intron
2. The fourth splice-site mutation was at the2 position
of the splice acceptor in intron 1. Analysis by RT-PCR
of lymphoblast RNA from probands 2 and 3 (fig. 2),
who have different splice-site mutations at the 5 po-
sition in intron 1, reveals the use of two alternate splice-
donor sites from within exon 1 and intron 1. The major
product (A), which includes part of intron 1, would re-
main in-frame with an 18-amino-acid insertion. The mi-
nor splice product (B) would not retain the reading
frame. RT-PCR analysis of RNA from proband 4, who
has an acceptor-splice-site mutation at the 2 position
of intron 1, revealed two different splice products; the
major product resulted from exon 1 splicing directly to
exon 3 (D), which retains the reading frame, and the
other product resulted in a change of reading frame (C),
by use of an alternate splice-acceptor site from within
exon 2.
The deletions, insertions, and stop mutation were dis-
tributed throughout the gene, from exon 1 through exon
10 (fig. 1). One of the missense mutations was in exon
3, and the other four missense mutations occurred in
exon 8. Analysis of 50 control X chromosomes did not
detect the missense mutation seen in proband 7 with
Barth syndrome. Analysis of 75 control X chromosomes
did not identify any of the detected mutations seen in
exon 8 in probands 8–11. The presence of missense
changes in exon 8 was analyzed by use of direct sequence
analysis, and the change in exon 3 was analyzed by
restriction digestion. None of the mutations that we de-
tected were in any of the alternatively spliced exons (i.e.,
exons 5–7) described by Bione et al. (1996). Of the 14
probands, 7 had either affected relatives or mothers who
were shown by direct sequencing or restriction analysis
to carry the same mutation. Inheritance in each of these
pedigrees was consistent with an X-linked pattern. One
proband (proband 2) is assumed to have a new mutation,
since his mother was shown not to carry the mutation
and he has no affected relatives.
Genotype-Phenotype Correlation
The G4.5 mutations were categorized as causing either
(1) only single-amino-acid changes (missense mutations)
or (2) significant alterations of the G4.5 protein product
(splice-site, frameshift, or nonsense mutations). In ad-
dition, we examined mutations that would affect only
the longer mRNA species (exons/introns 1 and 2) and
compared these mutations with those that would affect
all the mRNA species.
When we scored the clinical severity of the cardiomyo-
pathy (mild [i.e., not requiring medical therapy and not
restricting activity], moderate [requiring medication and
restricting activity], and severe [requiring aggressive
medical therapy and transplantation and/or resulting in
death]) and its age at onset, we found no correlation
between genotype and either severity or age at onset of
the cardiac phenotype. Whereas most patients with mu-
tations in exons/introns 1 and 2 had only mild to mod-
erate cardiac disease, proband 5, with an exon 2 mu-
tation, had severe disease. In addition, two patients with
missense mutations affecting exon 8 had severe cardiac
disease, whereas other missense mutations in this same
exon were associated with milder cardiac disease.
When the severity of the neutropenia was character-
ized by the lowest recorded neutrophil count and the
presence or absence of otherwise unexplained severe in-
fections, again no clear correlation with genotype could
be discerned. Patients with severe neutropenia (absolute
neutrophil count !300) and frequent bacterial infections
included those with mutations in exons/introns 1 and 2
and those with mutations in exons 8–10. Similarly, there
was no relationship between specific mutations and the
magnitude of the 3-methylglutaconic aciduria/acidemia.
Discussion
We have identified mutations in the G4.5 gene in 14
probands with Barth syndrome. The individual G4.5
mutations segregating with the Barth phenotype are het-
erogeneous and are distributed throughout the gene, in
multiple exons and in the exon/intron boundaries. How-
ever, a clustering of mutations in the first two exons and
introns and in exons 8 and 9 is evident in our survey
and in the report by Bione et al. (1996). Thus, a staged
sequencing strategy examining the first two exons and
exon/intron boundaries and exons 8 and 9 would have
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Table 2
Mutational Analysis of 14 Probands and Family Members
Family Relation Type of Mutation Nucleotide Position Exon/Intron Effect of Mutation Reference
1 Probanda 2-bp deletion 341–342 Exon 1 Frameshift after amino acid 18
Mothera,b
2 Proband GrA 3955 Intron 1 Splice donor
3 Probanda GrC 3955 Intron 1 Splice donor Pedigree 2 in Kelley et
al. (1991)
Mothera
4 Proband ArG 396-2 Intron 1 Splice acceptor
Motherb
5 Probanda 1-bp deletion 459 Exon 2 Framehift after amino acid 57 Pedigree 3 in Kelley et
al. (1991)
6 Probanda TrG 5262 Intron 2 Splice donor Case 4 in Christodou-
lou et al. (1994)
7 Probanda CrT 568 Exon 3 Arg94rCys
Mothera,b
8 Proband GrA 878 Exon 8 Gly197rGlu Pedigree 5 in Kelley et
al. (1991)
9 Proband GrA 877 Exon 8 Gly197rArg Case 2 in Christodou-
lou et al. (1994)
10 Proband TrA 914 Exon 8 Ile209rAsp
11 Proband TrC 923 Exon 8 Leu212rPro
Motherb
12 Proband 1-bp deletion 972 Exon 9 Frameshift after amino acid 229 Case 1 in Christodou-
lou et al. (1994)




14 Proband 1-bp insertion 988 Exon 10 Frameshift after amino acid 234 Case 5 in Christodou-
lou et al. (1994)
Cousinb Case 6 in Christodou-
lou et al. (1994)
a Mutation was verified by restriction-enzyme analysis: AlwNI (family 3), ApaI (family 5), AvaII (family 1), KpnI (family 6), and SfaNI
(family 7).
b Mutation was verified by sequence analysis.
Figure 1 Location of mutations in G4.5 gene in 14 Barth syndrome families. Exons are depicted by unblackened boxes; introns are
represented by lines; and alternatively spliced exons are denoted by an asterisk (*). The start and stop sites of translation are shown. Each
mutation is shown individually, although when two mutations affect the same amino acid or splice-site nucleotide, only one line has been used.
S  splice site; N  nonsense mutation; M  missense mutation; D  deletion; and I  insertion.
identified mutations in 12 of the 14 pedigrees that we
studied and in 15 of 18 pedigrees now reported in the
literature. Since the overall size of the G4.5 gene is rel-
atively small, a direct-sequencing approach initially ex-
amining these portions of the gene may be an economical
solution to the prospective identification of mutations
in other patients and may obviate the need to utilize a
screening strategy such as SSCP.
Our mutational analysis has several implications with
regard to the function of the G4.5 protein(s). Bione et
al. (1996) identified two 5′ start sites for the G4.5
mRNAs, predicting two separate sets of alternatively
spliced mRNA products. The longer mRNA species,
which include exons 1 and 2, were ubiquitously ex-
pressed in all tissues examined by Bione et al., whereas
the shorter mRNA species were expressed only in leu-
kocytes and fibroblasts. This distribution of mRNAs
suggests that some mutations might have differential tis-
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Figure 2 A, RT-PCR of total RNA from lymphoblasts of three
Barth syndrome patients with splice-site mutations. Oligonucleotides
F2 and R9 were used in the PCR. Arrows indicate products (i.e., A–D
and wild type [WT]) that have been sequenced. Marker sizes are shown
to the right of the gel. C  control RT-PCR. B, Diagram of splice
products present in PCR reactions, as determined by sequencing.
sue effects. However, mutations in exons 1 and 2 are
clearly capable of producing the complete Barth phe-
notype, including neutropenia. This suggests that the
longer mRNA species are nonetheless essential for G4.5
protein function in leukocytes. In addition, because mis-
sense mutations in exons 3 and 8 were also associated
with classic Barth syndrome, there probably are several
regions of the G4.5 protein that are essential for its func-
tion. Further studies will clearly be necessary to establish
the function of these novel proteins.
Five of the 14 probands whom we studied had mis-
sense mutations affecting exon 3 (1 proband) and exon
8 (4 probands). These mutations would result in single-
amino-acid changes in the protein product(s) of the G4.5
gene. Thus, it is conceivable that these could represent
polymorphic variants and not causative mutations.
However, we have not been able to detect these changes
in either 50 control chromosomes normal for exon 3 or
75 control chromosomes normal for exon 8. In addition,
when our data are combined with the data reported by
Bione et al. (1996), the presence of a G4.5 mutation was
identified in 18 subjects with all of the cardinal mani-
festations of Barth syndrome, whereas none of these mu-
tations were detectable in a total of 175 normal control
chromosomes. These data strongly suggest that these
mutations cause Barth syndrome.
In addition to the apparent lack of correlation between
the G4.5 mutations and the clinical phenotype in Barth
syndrome patients, we have found that there can be sub-
stantial phenotypic variation for a single G4.5 mutation.
For example, in one of our study’s previously reported
families in which the proband had a phenotype of mod-
erate severity, there were one maternal uncle who died
at 3 mo, from cardiac disease, and a second, 35-year-
old maternal uncle with the mutation and increased 3-
methylglutaconic aciduria but a normal echocardiogram
and no history of either heart disease or bacterial infec-
tions in childhood (pedigree 2 of Kelley et al. 1991).
These observations suggest that other environmental or
genetic factors influence the phenotypic severity of Barth
syndrome. It should be noted that changes in the man-
agement of cardiac disease and bacterial infections, in
recent years, may significantly influence the clinical
course of Barth syndrome. Such management differences
may explain why 17 of the 18 confirmed or suspected
cases in the original description of Barth syndrome
(Barth et al. 1983) died either suddenly during infancy
or from documented cardiac disease or sepsis.
All male patients with the triad of dilated cardiomy-
opathy, neutropenia, and increased 3-methylglutaconic
aciduria whom we tested had a detectable mutation in
the G4.5 gene. Thus, at this time there is no evidence
for genetic heterogeneity of this phenotype. There are a
number of inherited metabolic disorders that include, as
a cardinal manifestation, cardiomyopathy in infancy or
early childhood. Very few of these disorders are asso-
ciated with neutropenia. However, because the absolute
neutrophil count in Barth syndrome may fluctuate con-
siderably, there may be other cases of Barth syndrome
in the literature that are recorded only as X-linked di-
lated cardiomyopathy. The presence of increased 3-
methylglutaconic aciduria in this clinical setting appears
to be relatively specific for Barth syndrome (Kelley et al.
1991).
Although there have been a few reported cases of hy-
pertrophic cardiomyopathy with neutropenia and in-
creased 3-methylglutaconic aciduria, all of these have
had clinical and laboratory abnormalities quite different
from those of Barth syndrome. They are most likely
defects of the mitochondrial respiratory chain (Gibson
et al. 1992; Holme et al. 1992; Ibel et al. 1993). It is
also interesting to note that, despite the X-linked inher-
itance of Barth syndrome and the identification of many
females carrying G4.5 mutations, there have been no
reports of females with classic Barth syndrome. More-
over, all obligate-heterozygote females whom we have
tested have had normal levels of 3-methylglutaconic acid
(R. I. Kelley, unpublished observations). It is clear from
our study and others that an initial evaluation for the
presence of increased 3-methylglutaconic aciduria is im-
portant in patients with unexplained cardiomyopathy or
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neutropenia. For pedigrees in which the proband has the
classic Barth phenotype and associated metabolic ab-
normalities, initial characterization of the G4.5 gene se-
quence, focusing on exons 1, 2, 8, and 9, is a reasonable
approach toward identification of the responsible mu-
tations, for subsequent carrier detection, pedigree anal-
ysis, and genetic counseling.
We have not yet examined the possible role of G4.5
mutations in patients with phenotypes that have some,
but not all, of the cardinal clinical manifestations of
Barth syndrome. Familial dilated cardiomyopathy in pa-
tients without other features of Barth syndrome but sus-
pected to be allelic with Barth syndrome has been re-
ported (Hodgson et al. 1987; Gedeon et al. 1995). Two
recent reports identify G4.5 mutations in patients with
familial X-linked dilated cardiomyopathy and in a fam-
ily with neonatal, lethal noncompaction of the left ven-
tricular myocardium (Bleyl et al. 1997; D’Adamo et al.
1997). For some of the subjects reported in these ped-
igrees, neutropenia was an inconsistent finding, and the
presence of abnormal 3-methylglutaconic aciduria was
not detected. Future studies will need to examine the
role of G4.5 mutations, both in patients with 3-meth-
ylglutaconic aciduria and cardiomyopathy without neu-
tropenia and in patients with 3-methylglutaconic acid-
uria alone (e.g., patient II-4 in pedigree 2 of Kelley et
al. 1991). In addition, mutational screening may be use-
ful for identification of patients who have not yet man-
ifested cardiomyopathy but who, on the basis of family
history, may be at risk.
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